ConductScience.org, home
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
API referenceFor AI assistants

Trial · NCT05169515

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryPercentage of participants with dose-limiting toxicities (DLTs) [dose escalation]Until 90 days after the final dose of study treatment
PrimaryPercentage of participants with adverse events [all cohorts]Until 90 days after the final dose of study treatment
Primary
Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]
Up to 2 years after start of primary study treatment
PrimaryTolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]Until 90 days after the final dose of study treatment
SecondaryBest CR rate, defined as the proportion of participants whose best overall response is a CR during the study, as determined by the investigator using Lugano 2014 criteria [all cohorts]Up to 1 year after primary study treatment
SecondaryBest ORR (CR or PR at any time) on study as determined by the investigator using Lugano 2014 criteria [dose escalation]Up to 2 years after primary study treatment
SecondaryDuration of response (DOR) as determined by the investigator using Lugano 2014 criteria [all cohorts]Up to 2 years after primary study treatment
SecondaryProgression-free survival (PFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]Up to 2 years after primary study treatment
SecondaryEvent-free survival (EFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]Up to 2 years after primary study treatment
SecondaryOverall survival (OS) [dose expansion]Up to 2 years after primary study treatment
SecondaryPercentage of participants with adverse events [dose expansion]Until 90 days after the final dose of study treatment
SecondarySerum concentration of subcutaneous (SC) mosunetuzumab [all cohorts]Up to 2 years after primary study treatment
SecondarySerum concentration of intravenous (IV) glofitamab [all cohorts]Up to 2 years after primary study treatment
SecondarySerum concentration of CC-220 and CC-99282 (CELMoDs) [all cohorts]Up to 12 cycles of study treatment (cycle length = 21 or 28 days for Arm 1 and 21 days for Arm 2)
SecondaryTolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose expansion]Until 90 days after the final dose of study treatment

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05169515/registered

API referenceFor AI assistants